A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.

Inclusion Criteria: * Had participated in a GW clinical study to investigate the effects of Sativex® on peripheral neuropathic pain and had completed the study. This must have been within the last seven days * Had complied with all of the study requirements in the preceding GW parent RCTs, including the completion of diary cards and study questionnaires * Had shown tolerability to the study medication in a preceding GW study * Was expected, in the opinion of the investigator, to gain clinical benefit from receiving Sativex® therapy * Ability (in the investigators opinion) and willingness to comply with all study requirements, including the completion of diary cards and study questionnaires * Agreement for the responsible authorities (as applicable in individual countries), their primary care physician, and their consultant, if appropriate, to be notified of their participation in the study. Exclusion Criteria: * History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition * Known or suspected history of alcohol or substance abuse * History of epilepsy or recurrent seizures * Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medication Evidence of cardiomyopathy * Experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or had a cardiac disorder that, in the opinion …